

## Disclosures

### Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Affinia Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Apple	Research/Research Grants ‡ Apple Heart and Movement Study	Significant (>= \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Prevention
Atman Health	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	General Cardiology
Bloomer Tech	Stock	None (\$0)	Arrhythmias and Clinical EP
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ Trial of p38 inhibitor in lamin associated cardiomyopathy	None (\$0)	Heart Failure and Cardiomyopathies
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
TMAPrecision Medicine	Stock	Modest (< \$5,000)	Other
Verily	Research/Research Grants	Significant (>= \$5,000)	Prevention

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association ‡ Apple	Research/Research Grants ‡ Apple Heart and Movement Study	Significant (>= \$5,000)	Prevention
American Heart Association ‡ Verily and AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	Prevention
NIH Research Grants	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	Congestive heart failure and sudden death	Plaintiff	Missed diagnosis of myocarditis or cardiomyopathy	Modest (< \$5,000)
2017	Coronary artery diagnosis	Plaintiff ‡ none	Missed diagnosis of ACS	Significant (>= \$5,000)
2015	Aortic disease	Defendant	Decision making and responsibility with regard to aortic root surveillance which eventually led to fatal dissection.	Modest (< \$5,000)
2015	Diagnosis of myocardial abnormality	Plaintiff	Misinterpretation of EKG	Modest (< \$5,000)

Year	Case Title	Represented	Description	Compensation
2015	Inherited heart disease	Defendant	Complications of sepsis in inherited heart disease	Modest (< \$5,000)
2015	Clinical evaluation of vascular access complications	Plaintiff	Standard of care	None (\$0)

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/4/2020

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/4/2020

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 10/4/2020

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 9/27/2022

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.